William Webster, PharmD, FCCP

CURRICULUM VITAE OF:

William B. Webster, Pharm. D., FCCP

Home Address 9525 Blind Pass Rd. # 1001 St. Pete Beach, Florida 33706

Home Telephone (727) 363-0072

Education 

Doctor of Pharmacy - 1984 College of Pharmacy, University of Florida Gainesville, Florida

B.S. Pharmacy College of Pharmacy, University of South Carolina Columbia, South Carolina

Professional Experience

Medical Rounds, Inc 
 9525 Blind Pass Rd 2008 to Present Unit 805 St Pete Beach, FL 33706

2012 Pfizer Medical Education Group Bacterial Infections External Review Panel

2005 to 2009 Schering-Plough Corporation (Merck) 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530 Global Medical Affairs Regional Medical Science Specialist, Infectious Diseases 
2004.5 Regional Medical Science Specialist, Respiratory/Allergy Territory: Southeast US

January 4, 2002 to October 29, 2004 
Aventis (Sanofi) 300 Somerset Corporate Boulevard Bridgewater, NJ 08807-0977 Medical Scientific Manager Medical Affairs Territory: Central and North Florida

Director, Clinical Research 2000 to 2002
 Research & Development Bay Pines VA Medical Center, Bay Pines, Florida

Clinical Education/Programs Manager 1984 to 2000 
Department of Pharmacy Services Bay Pines VA Medical Center, Bay Pines, Florida

Residency Program Director 1994 to 1999 
Department of Pharmacy Services Bay Pines VA Medical Center, Bay Pines, Florida

Director, Biotechnology Research Group 1992 to 2002 
Bay Pines VA Medical Center, Bay Pines, Florida

Clinical Pharmacist Specialist, Critical Care Pharmacotherapy 1984 to 2000 
Bay Pines VA Medical Center, Bay Pines, Florida

Clinical Coordinator 1984 to 2000 Department of Pharmacy Services Bay Pines VA Medical Center, Bay Pines, Florida

Director of Pharmacy, Student Health Services 1981 East Carolina University

Assistant Director of Pharmacology and Pharmacy Services 1979 to 1981 
East Carolina University School of Medicine Department of Family Practice, Greenville, North Carolina

Private Practice, Fairmont, North Carolina 1968 to 1978 
Owner, Webster’s Pharmacy, Inc.

Internship, Greenville South Carolina 1966 to 1967

Academic 

1997 to 2002 Appointments Clinical Professor of Pharmacy NOVA Southeastern University, Ft. Lauderdale

2000 to 2002 Adjunct Professor Mercer University, Southern College of Pharmacy Atlanta, Georgia

1994 to 2000 Clinical Faculty Mercer University, Southern College of Pharmacy Atlanta, Georgia

1989 to 1997 Clinical Associate Professor of Pharmacy Southeastern University, Miami, Florida

1989 to 2002 Clinical Associate Professor of Pharmacy University of Florida, Gainesville, Florida 1985 to 1989 Clinical Assistant Professor of Pharmacy University of Florida, Gainesville, Florida

2000 to 2002 Courtesy Adjunct Professor, Department of Natural Science St. Petersburg Junior College, St Petersburg, Florida

1979 to 1981 Lecturer, East Carolina University School of Medicine

Board Certification

 August 17, 1991 Pharmacotherapy Board, BPS # 291140 Board of Pharmaceutical Specialties American Pharmaceutical Association

October 3, 1998 Recertified by examination

October 1, 2005 Recertified by examination

October 2013 Retired

Additional Training

 May 1990 Oak Ridge Associated Universities Radiopharmaceutical Internal Dose Calculation Techniques Course Oak Ridge Tennessee

Awards and Honors

 2005 Elected Fellow American College of Clinical Pharmacy

1992 Scientific Poster Award: Pharmacy World Congress International Pharmaceutical Federation 52nd International Congress of Pharmaceutical Sciences of FIP

1990-1991 Syntex Award: Preceptor of the year Southeastern University, College of Pharmacy, Miami

Elected 1976 Fellowship: American College of Apothecaries

Elected 1976 Membership: North Carolina Academy of Pharmacy

Other Awards 2007 Leadership Recognition Award Schering-Plough, Global Medical Affairs

2003 Regional Team Player Award Aventis, Medical Scientific Team

Reviewer/Item Writer

 2003 to present Journal of Pharmaceutical Sciences

July 1997 UHC Drug Monographs Series

December 1996 to present Annals of Pharmacotherapy

August 1996 to present Pharmacotherapy

December 1991, April 1999 Board of Pharmaceutical Specialties Pharmacotherapy Examination

Post Doctoral Fellows

July 1991 Post-Doctoral Post-Doctoral Fellowship established Preceptor Biotechnology: Antibody Immunoconjugates and Immunotherapeutics
Fellows: 1991-1992 Jamini Patel, Ph.D. 1996.1997 Andrew Nasarri, M.D. Candidate

General Post-Doctoral Research Fellowship Fellow: 1999-2000 Andrew Nasarri, M.D.

Graduate Student July 1993 Preceptor Mathematics/Biostatistics Fellow: Marnie S. Hatton, Department of Mathematics University of South Florida, Tampa Florida

Professional Activities

Elected Society of Infectious Disease Pharmacist (SIDP) Societies 

American Pharmaceutical Association American College of Clinical Pharmacy Research Affairs Committee 1998-1999 

Research Affairs Committee 1999-2000 Education Affairs Committee 2003-04 

Education Affairs Committee 2004-05 Credentials Committee 2006-07

Licensure 

1982 Florida No. PS0019948 1967 South Carolina No. 3462 (inactive status)

Research

 1995 Supporting authority for hearing before FDA/CBER 99mTc-Labelled Anti-Granulocyte Antibody Fab, Sulesomab (LeuScanTM)

1986 to 2002 Pharmacokinetics and Tissue Distribution of Radiolabeled Monoclonal Antibodies and other Radioimmunodiagnostics and Radioimmunotherapeutics In association with: Steven J.Harwood, M.D., Ph.D., Robert G. Carroll, M.D.

1982 to 1984 Stereospecific Binding of Propranolol to Serum Proteins In association with: John A. Pieper, Pharm.D.

1980 to 1982 Determination of Pancreatic Alpha Subtype Receptors by Radioligand Binding Technique In association with: Mona M. McConnaughey, Ph.D.

Publications 

Webster WB, McConnaughey MM. Clonidine and Glucose Intolerance. Drug Intelligence and Clinical Pharmacy 1982; 16:325-328.

Kaplan RF, Feinglass NC, Webster WB, Mudra S. Phenelzine Overdose Treated with Dantrolene Sodium - JAMA 1986; 255: 642-644.

Harwood SJ, Webster W, et al. Comparison of Human Biodistribution and Differences Between 131Iodine and 111Indium Labeled B72.3 Monoclonal Antibody. Cancer Research (Suppl.), 1990; 50: 932s-936s.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA. Pharmacokinetics of 111In-Labeled B72.3 Monoclonal Antibody in Colorectal Cancer Patients. The Journal of Nuclear Medicine 1992; 33: 498-504.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA. A reply to: Mean Time Parameters Reveal Differences in the Pharmacokinetics of Indium-111 and Iodine-131-labeled B72.3 Monoclonal Antibody. The Journal of Nuclear Medicine 1992; 33: 2248-2249.

Webster WB, Laven DL. Pharmacokinetics and Biologic Distribution Studies of Indium-111-Labeled Monoclonal Antibodies. New Perspectives in Cancer Diagnosis and Management 1993; 1: 12-19.

Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, Patel JU, Webster WB and Carroll RG. Use of Technetium Anti-Granulocyte Monoclonal Antibody Fab' Fragments for the Detection of Osteomyelitis. Cell Biophysics 1994; 24/25: 99-107.

Laucka PV, Webster WB, Kuch J. Pharmacist Review to Simplify Medication Regimens in A VAMC Primary Care Clinic. Journal of Pharmacy Technology 1996; 12: 62-6.

Hakki S, Harwood SJ, Morrissey MA, Camblin JG, Laven DL, Webster WB. Comparative Study of Monoclonal Antibody Scan in Diagnosing Orthopaedic Infection. Clinical Orthopaedics and Related Research 1997; 335: 275-285.

Banoob DW, McCloskey WW, Webster W. Risk of gastric injury with enteric- versus nonenteric-coated aspirin. Ann Pharmacother. 2002 Jan;36(1):163-6

Harwood SJ, Gibbons LK, Goldner PJ, Webster WB, Carroll RG. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure. Cancer. 2002 Feb 15;94(4 Suppl):1358-62.

Michael O Chaffman, William B Webster, John T Winiecki Efficacy and Safety Evaluation of a Large Niacin Therapeutic Interchange Program Ann Pharmacother May 2013 47: 657-664

Book Chapter

 Harwood SJ, Webster WB, et al. Phase I Clinical Trial of 111Indium 7E11-C5.3 (CYT-356) for the Detection of Prostate Carcinoma. in Monoclonal Antibodies 2: Applications in Clinical Oncology. Epenetos E, Editor. Chapman & Hall Medical, London. 1993: 305-320.

Contributing Reviewer 

Peters DH, Fitton A. (Webster WB Reviewer) Satumomab Pendetide: A preliminary Review of Its Use in the Diagnosis of Colorectal and Ovarian Cancer. Clinical Immunotherapy 1995; 3(5):395-408.

Grant KL, Abarca J. (Webster WB Contributing Reviewer) UHC Drug Monograph: MIBEFRADIL. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. December 1997.

Leslie D. (Webster WB Contributing Reviewer)UHC Drug Monograph: CARVEDILOL. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. December 1997.

Gardner SF (Webster WB Contributing Reviewer)UHC Drug Monograph: ANGIOTENSIN II RECEPTOR ANTAGONIST. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. August 1998.

Tortorice P (Webster WB Contributing Reviewer) UHC Drug Monographs: RITUXIMAB. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. December 1999.

Invited Oral Presentations of Research

 Pharmacokinetic and Bioequivalence Studies of Targeted Delivery Systems: Evaluation of Radio-Immuno-Pharmaceuticals as Drugs. Given at: 8th Annual DIA Biotechnology Workshop, BIOTECHNOLOGY: Global Perspectives, Dana Point, California, March 6-7, 2000.

Pharmacokinetic Studies of Radiolabeled Monoclonal Antibodies: Non-Compartmental and Mean-Time Analysis. Given at: Midyear Clinical Meeting, American Society of Hospital Pharmacist, New Orleans, December 8-12, 1991.

Podium Presentations of Original Research 

Diagnostic Scanning in Orthopaedic Infections: A Comparative Study of Tc-99m MAb Scans with In-111 WBC and Tc-99m MDP Bone Scans. Hakki, S, Harwood, SJ, Camblin, JG, Morrissey, MA, Laven, D, and Webster, WB. Given at: Annual Meeting 1996, American Academy of Orthopaedic Surgeons, Atlanta, Georgia, February 22 to 26 1996.

Effect of Human Antimouse Antibody, HAMA, on Plasma Mean-time Pharmacokinetics and Distribution of 111In-radiolabeled B72.3 Monoclonal Antibody in Colorectal Cancer Patients. Webster, WB. Given at: The Seventh International Symposium On Radiopharmacology, Boston, Massachusetts, June 3-6, 1991.

Patient Interpretation of the Chemstrip bG Method of Home Glucose Monitoring. Webster, WB. Given at: Fourteenth Annual Southeastern Conference for Post-Graduate Pharmacy Education and Training, Athens Georgia, March 12, 1983.

Published Abstracts 

Webster WB, Pieper JA. Stereospecific Protein Binding of Propranolol. Abstract in: Drug Intelligence and Clinical Pharmacy 1985; 19:463.

Harwood SJ, Webster WB, et al. Pharmacokinetics and Tissue Distribution of 111In-ZCE-025 Anti-CEA Monoclonal Fab' Fragments. Abstract in: J. Nuclear Med. 1987; 20: 1791.

Harwood SJ, McDonald LM, Elkin MF, Laven DL, Sinni BJ, Webster WB, Carroll RG. Biodistribution Differences in Nude Mice and Man. Abstract in: J. Nuclear Med. 1988;29: 2029.

Harwood SJ, Carroll RG, DeRuzzo ST, Webster WB, et al. Biodistribution of 111In-ZCE-025 Anti-CEA Monoclonal Fab Fragments. Abstract in: J. Nuclear Med. 1988; 29: 896.

Webster WB, et al. Analysis of Plasma and Tissue Distribution Pharmacokinetics for 111IN-B72.3 Monoclonal Antibody in Colorectal Cancer Patients. Abstract in: Antibody Immunoconjugates, and Radiopharmaceuticals. 1988; 3: 78.

Webster WB, et al. Development of Mean Transit and Residence Time Analysis of Radiolabeled Murine Monoclonal Antibody Distribution and Clearance. Abstract in: Pharmacotherapy. 1988;10: 54.

Webster WB, et al. Plasma and Tissue Distribution Pharmacokinetics of 111In Murine Anti-CEA Monoclonal Antibody in Colorectal Cancer Patients; Abstract in: European Journal of Nuclear Medicine. 1988; 10: 574.

Webster WB, et al. Pharmacokinetics of 111In-ZCE025 Mab in Colorectal Cancer Patients: Effect of CEA on Mean-Time Parameters; Abstract in: Antibody Immunoconjugates and Radiopharmaceuticals. 1992; 5: 141.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Determining In Vivo 111In-B72.3 Specific Binding by Pharmacokinetic Analysis of Plasma Clearance; Abstract in: Antibody Immunoconjugates and Radiopharmaceuticals. 1992; 5(3): 356.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Plasma Pharmacokinetics of 111In-CYT-356 Prostate Antibody; Abstract in: Antibody Immunoconjugates and Radiopharmaceuticals. 1992; 5(3): 356.

Harwood SJ, Camblin JG, Morrissey MA, Laven DL, Zangara LM, Patel JU, Carroll RG, Webster WB. Comparison of TC-99m Immu-RAIDTM-MN3 Anti-granulocyte MAb FAb' Fragments and In-111 WBC's for detection of Osteomyelitis; Abstract in: J. Nucl. Med. 1994; 89: 35P.

Evans Branch, III, Lynne C. Krop, J. Mark Trotter, and William B. Webster. Cephalosporin Usage and the Emergence of Enterococcal Isolates; Abstract in: International Pharmaceutical Abstracts. 1995; 32(21): 2329.

Webster WB, Harwood SH, Carroll RG, Morrissey M, Hakki S. Comparative Pharmacokinetics, Dosimetry, and In-Vivo stability of two formulations of 99mTc-Labeled Anti-granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoscanTM); Abstract in: Pharmacotherapy. 1996; 16(1): 131-2.

Hakki S, Harwood SJ, Morrissey MA, Camblin JG, Laven DL, Webster WB. Comparative Study of Monoclonal Antibody Scan in Diagnosing Orthopaedic Infections: A Comparison of Tc-99m Monoclonal Antibody Scans, with Indium-111 White Blood Cell and Technetium-99m Medronate DiphosphateBone Scans Orthopaedic Transactions 1996;20.

Hakki S, Harwood SJ, Morrissey MA, Camblin JG, Laven DL, Webster WB. Comparative Study of Monoclonal Antibody Scan in Diagnosing Orthopaedic Infection. Clinical Orthopaedics and Related Research 1996; 335: 275-285. Abstracted in Yearbook of Nuclear Medicine, 1998.

William B. Webster, Tina Vo,, Andrew F. Nasseri, Steven J. Harwood, Sam Hakki, Robert G. Carroll, Michele Morrissey, John Camblin, Tatjana Webster. An Open Label Study Evaluating the Pharmacokinetics of 99mTechnetium P280 (Diagnostic Agent) in Patients at Risk for Venous Thrombosis; Abstract in: Pharmacotherapy. 1999;19(10): 1216-7.

Webster WB, Harwood SJ, Carroll, RW, Gibbons L, Sochet A, Tantranond P, Morrissey M, Goldner P, Deruzzo S, Fahrendorf T. Patient Specific Radioimmunotherapy of Non-Hodgkin=s Lymphoma with Iodine-131-Anti-B1 Antibody (iodine I 131 Tositumomab): Pharmacokinetic Dosing. Abstract in: Pharmacotherapy. 2000;20(3): 352-3.

Webster WB, Harwood SJ, Carroll R, Hakki S, Camblin J, Gibbons L, Morrissey M, Goldner, P, Deruzzo S, Fahrendorf T. Bioequivalence Pharmacokinetic Studies of Two Formulations of 99mTc-Labelled Anti-Granulocyte Antibody Fab= Fragment, Sulesomab (LeuScanTM): Evaluation of a Radiopharmaceutical As a Drug B What Difference Is Important. Abstract in: Cancer Biotherapy & Radiopharmaceuticals. 2000;15(4): 411.

Webster WB, Harwood SJ, Carroll R, Gibbons L, Sochet A, Tantranond P, Morrissey M. Outpatient Therapy of Non-Hodgkin=s Lymphoma with Iodine-131-Anti-B1 Antibody: Innovative Administration Techniques for Minimizing Radiation Exposure. Abstract in: Cancer Biotherapy & Radiopharmaceuticals. 2000;15(4): 414.

Poster Presentations 

Bioequivalence Pharmacokinetic Studies of Two Formulations of 99mTc-Labelled Anti-Granulocyte Antibody Fab= Fragment, Sulesomab (LeuScanTM): Evaluation of a Radiopharmaceutical As a Drug B What Difference Is Important. Webster WB, Harwood SJ, Carroll R, Hakki S, Camblin J, Gibbons L, Morrissey M, Goldner, P, Deruzzo S, Fahrendorf T. Presented at: Eighth Conference on Radioimmunodection and Radioimmunotherapy of Cancer, Princeton, NJ, October 12-14, 2000.

Outpatient Therapy of Non-Hodgkin=s Lymphoma with Iodine-131-Anti-B1 Antibody: Innovative Administration Techniques for Minimizing Radiation Exposure. Webster WB, Harwood SJ, Carroll R, Gibbons L, Sochet A, Tantranond P, Morrissey M. Presented at: Eighth Conference on Radioimmunodection and Radioimmunotherapy of Cancer, Princeton, NJ, October 12-14, 2000.

Patient Specific Radioimmunotherapy of Non-Hodgkin=s Lymphoma with Iodine-131-Anti-B1 Antibody (iodine I 131 Tositumomab): Pharmacokinetic Dosing. Webster WB, Harwood SJ, Carroll, RW, Gibbons L, Sochet A, Tantranond P, Morrissey M, Goldner P, Deruzzo S, Fahrendorf T. Presented at: 2000 Spring Practice and Research Forum, American College of Clinical Pharmacy, Monterey, California, April 2-5, 2000.

An Open Label Study Evaluating the Pharmacokinetics of 99mTechnetium P280 (Diagnostic Agent) in Patients at Risk for Venous Thrombosis. William B. Webster, Tina Vo,, Andrew F. Nasseri, Steven J. Harwood, Sam Hakki, Robert G. Carroll, Michele Morrissey, John Camblin, Tatjana Webster; Presented at: 1999 Annual Meeting of the American College of Clinical Pharmacy, Kansas City, Missouri, October 24-27, 1999.

Outpatient Therapy of Non-Hodgkin=s Lymphoma with Iodine-131-Anti-B1 Antibody : Innovative Administration Techniques for Minimizing Radiation Exposure. Webster WB, Harwood SJ, Carroll, RW, Gibbons L, Schoet A, Tantranond P, Morrissey M. Presented at: International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, October 14-16, 1999.

Comparative Pharmacokinetics, Dosimetry, and In-Vivo stability of two formulations of 99mTc-Labeled Anti-granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoscanTM). Presented at: 1996 Winter Practice and Research Forum, American College of Clinical Pharmacy, Monterey, California, February 11-14, 1996.

Cephalosporin Usage and the Emergence of Enterococcal Isolates, Evans Branch, III, Lynne C. Krop, J. Mark Trotter, and William B. Webster. Presented at: Midyear Clinical Meeting, American Society of Heath-System Pharmacist, Las Vegas, Nevada, December 3-7 1995.

Plasma Pharmacokinetics of 99m TC-Immu-4 Fab' in Colorectal Cancer Patients. Webster WB, et.al. Presented at: The Fifth Conference on Radioimmunodection and Radioimmunotherapy of Cancer, Princeton, NJ, October 6-8, 1994.

Assessment of MAb Scanning for Osteomyelitis. Camblin JG, Hakki S, Harwood SJ, Morrissey MA, Patel JU, Laven DL, and Webster WB. Scientific Poster presented to Fourteenth Annual Meeting of the Orthopaedic Research Society, New Orleans, La, February 21-24, 1994.

Detection of Osteomyelitis Using TC-99m Immu-RAIDTM-MN3 Anti-granulocyte MAb FAB' Fragments; Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, Patel JU, Webster, WB, and Carroll, RG. Presented at: Southeastern Chapter, Society of Nuclear Medicine, Clearwater Beach, Florida, October 8-10, 1993.

Use of Technetium Anti-Granulocyte Monoclonal Antibody Fab' Fragments for the Detection of Osteomyelitis. Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, Patel JU, Webster WB and Carroll RG. Presented to: Tenth International Hammersmith Meeting, Paphos, Cyprus. May 3-5, 1993.

Determining In Vivo 111In-B72.3 Specific Binding by Pharmacokinetic Analysis of Plasma Clearance; Webster WB, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Presented at: Fourth Conference on Radioimmunodection and Radioimmunotherapy of Cancer, Princeton, NJ, Sept 16-19, 1992.

Plasma Pharmacokinetics of 111In-CYT-356 Prostate Antibody; Webster WB, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Plasma Pharmacokinetics of 111In-CYT-356 Prostate Antibody; Presented at: Fourth Conference on Radio-immunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, Sept 16-19, 1992.

A Multidisciplinary Team Approach in Determining the Clinical Significance of an Indium-111 labeled Monoclonal Antibody for Colorectal Carcinoma. Laven DL, Morrissey MA, Zangara L, Webster WB and Harwood SJ: Presented at: Pharmacy World Congress '92, FIP Section of Hospital Pharmacists, International Pharmaceutical Federation, Lyon, France, September 13-19, 1992.

Pharmacokinetics of 111In-ZCE025 MAb in Colorectal Cancer Patients: Effect of CEA on Mean-Time Parameters. Webster WB, Laven DL, Carroll RG, Harwood SJ and Morrissey MA: Presented at: Pharmacy World Congress '92, FIP Section of Hospital Pharmacists, International Pharmaceutical Federation, Lyon, France, September 13-19, 1992. (Scientific Poster Award)

Pharmacokinetics of In-111-B72.3 MAb with Antibody-Antigen (TAG-72) or Antibody-Antibody (HAMA) Binding. Webster WB, Harwood SJ, Carroll RG, Morrissey MA and Laven DL: Presented at: Pharmacy World Congress '92, FIP Section of Hospital Pharmacists, International Pharmaceutical Federation, Lyon, France, September 13-19, 1992.

Pharmacokinetics of 111In-ZCE025 Mab in Colorectal Cancer Patients: Effect of CEA on Mean-Time Parameters. Webster WB, et al. Presented at: Seventh International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, March 4-7, 1992.

Pharmacokinetics of In-111-B72.3 MAb with Antibody-Antigen (TAG-72) or Antibody-Antigen (HAMA) Binding. Webster WB, Harwood SJ, Carroll RG, Morrissey MA. Presented at: 32nd Annual Meeting, Southeastern Chapter, Society of Nuclear Medicine, Hollywood, Florida. October 11-13, 1991.

Factors Associated with the Withdrawal of Phenytoin In the Nursing Home Patient: A Practical Cost Saving Measure. Dierlam EM, Jordan CJ, Webster T, and Webster WB. Presented at: 26th ASHP Midyear Clinical Meeting, New Orleans, LA. December 8-12, 1991.

Plasma and Tissue Distribution Pharmacokinetics of 111In Anti-CEA Murine Monoclonal Antibody in Colorectal cancer Patients. Webster WB, et al. Presented at: 5th World Congress of Nuclear Medicine and Biology, Montreal, Quebec, Canada. August 26-31, 1990.

Development of Mean Transit and Residence Time Analysis of Radiolabeled Murine Monoclonal Antibody Distribution and Clearance. Webster WB, et al. Presented at: The 1990 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, California. August 5-8, 1990.

Analysis of Plasma and Tissue Distribution Pharmacokinetics for 111IN-B72.3 Monoclonal Antibody in colorectal cancer Patients. Webster WB, et al. Presented at: Fifth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, California. March 15-17, 1990.

Comparative Analysis of Liver and Splenic Uptake in a Monoclonal Antibody Study. Wilson LA, Harwood SJ, Webster WB, and Morrissey MA. Presented at: SE Chapter Meeting, Society Nuclear Medicine, Orlando, Florida, October 27-29, 1989.

Pharmacokinetics, Biodistribution, and Dosimetry of 111In Labeled Monoclonal Antibodies (MAb in Colorectal Cancer Patients. Webster WB, Laven DL, Carroll RG, and Harwood SJ. Scientific Poster presented at: 136th American Pharmaceutical Association Annual Meeting. Anaheim, CA, April 1989.

Usefulness of Gaussian Preprocessing, Iterative Post-Processing and Dual Isotope Organ Identification to Enhance Interpretability of 111In MoAb SPECT Studies. Harwood SJ, Webster WB, Morrissey MA, Zangara LM, Laven DL, and Carroll RG. Presented at: Symposium on Radiolabeled Antibodies in Cancer - A Critical Review of Current Technology., Princeton, NJ, January 19, 1989.

Biodistribution Differences of In-111 B72.3 MoAb in Nude Mice and Man. Harwood SJ, McDonald LM, Elkin MC, Laven DL, Sinni BJ, Webster WB, Carroll RG, Schmelter RF, Alvarez VL, and McGuire RT. Presented at: 29th Annual Meeting SE Chapter Society of Nuclear Medicine, Charleston, SC, November 4-6, 1988.

Inflammation Related Monoclonal Antibody Localizations in Colorectal Cancer Patients. Carroll RG, Harwood SJ, Stenzel M, Balducci L, Sinni B, Laven DL, and Webster WB. Presented at: Thirty-sixth Annual Meeting, Society of Nuclear Medicine, June 1988.

Comparison of Human Biodistribution Differences Between 131Iodine and111Indium Labeled B.72.3 Monoclonal Antibody. Harwood SJ, Webster WB, et al. Presented at: Second Conference on Radioimmunodetection and Radiotherapy of Cancer, Princeton, N.J., September 8-10, 1988.

Impact of a Pharmacy Based Phlebotomy service Integrated Into Aminoglycoside Clinical Pharmacokinetics Team. WB Webster, MJ Lewis, CC Morelli, L Barron, M Melville, H Chmel, Presented at: 23rd Annual ASHP Midyear Clinical Meeting, Dallas, Texas, December 4 - 8, 1988.

Biodistribution of 111In-ZCE-025 Anti-CEA Monoclonal Fab' Fragment, SJ Harwood, RG Carroll, ST DeRuzzo, WB Webster, D Laven, Presented at: The Society of Nuclear Medicine 35th Annual Meeting, San Francisco, California, June 17, 1988.

Dosimetry Implications of Tissue Distribution: Data for Fab Fragments of ZCE-025, RG Carroll, WB Webster, BJ Sinni, ST DeRuzzo, DL Laven, S J Harwood, Presented at: Third International Conference on Immunoconjugates for Cancer, American Association for Cancer Research, San Diego, California, February 4 - 6, 1988.

111Indium-Labeled Monoclonal Antibody Plasma Pharmacokinetics in Cancer Patients, WB Webster, et al. Presented at: 22nd Annual ASHP Midyear Clinical Meeting, Atlanta Georgia, December 6 - 10, 1987.

Pharmacokinetics and Tissue Distribution of ZCE-025 (Fab')2 In Humans. SJ Harwood, WB Webster, et al. Presented at: 28th Annual Meeting: The Society of Nuclear Medicine, Regional Meeting, Orlando Florida, October 16 - 17, 1987.

Stereospecific Binding of Propranolol. WB Webster, JA Pieper. Presented at: American College of Clinical Pharmacy, July 8, 1985; 6th Annual Meeting, Orlando

Signature W. Webster, Pharm.D.

RESEARCH

WILLIAM B. WEBSTER, Jr., Pharm.D., FCCP, BCPS (Retired)

GRANTS and APPROVED PROTOCOLS CLINICAL RESEARCH 

2000 to 2001 Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma with Radiolabled Humanized Immu-LL2: Treatment with 90Y-hLL2 IgG (#02340) Harwood SJ - Principal Investigator, Webster W, Co-Investigator. Immunomedics, Inc. 

2000 to 2001 Pharmacokinetics and Biodistribution of Multiple Administrations of CEA-Scan (Arcitumomab) Following Complete Resection of Primary Colorectal Carcinoma Harwood SJ - Principal Investigator, Webster W, Co-Investigator. Immunomedics, Inc. 

2000 to 2001 A Multicenter, Open Label Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy of Relapsed or Refractory Low-Grade or Follicular Transformed B-Cell Non-Hodgkin's Lymphoma Harwood SJ - Principal Investigator, Webster W, Co-Investigator. IDEC Pharmaceuticals 

2000 to 2001 Webster, W.B., Hakki, Sam I., Principal Investigators, Camblin JG, Nasseri A, Morrissey M, Hoeldtke J. Clinical Protocol for a Double-blind, Placebo-Controlled, Randomized Study of the Efficacy of Parecoxib 20 mg IV and Parecoxib 40 mg IV Given Postoperatively to Determine Narcotic-Sparing Effectiveness in a Post-Orthopedic Surgery Pain Model, IND # 52,613. SIREX/G.D. Searle. 

2000 to 2001 A Randomized, DB, Comparative Study of H376/95 and Enoxaparin for Prevention of Venous Thromboembolism following Total Hip Arthroplasty (BP#2300) Hakki, Sam I., Principal Investigator, Webster, W.B. Co-Investigator, Camblin JG, Nasseri A, Morrissey M, Hoeldtke J. Astra Zeneca 

2000 to 2001 Clinical Protocol for a Double-Blind, Placebo-Controlled Comparison of the Narcotic Sparing Activities of Valdecoxib 20 mg, Valdecoxib 40 mg, and Placebo in Post-Orthopedic Surgical Patients. Hakki, Sam I., Principal Investigator, Webster, W.B. Co-Investigator, Camblin JG, Nasseri A, Morrissey M, Hoeldtke J. SIREX/Searle 

1998 to 2001 Clinical Protocol For a Double-Blind, Placebo Controlled Evaluation of the Analgesic Activity of Parecoxib 20 mg IV and Parecoxib 40 mg IV Administered Pre-Operatively in a Postsurgical Orthopedic Pain Model. Protocol N93-99-02-037 US IND #52,613. Hakki, Sam I., Principal Investigator, Webster, W.B. Co-Investigator, Camblin JG, Nasseri A, Morrissey M, Hoeldtke J. SIREX/Searle 

1998 to 2001 CP-98-020 Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin=s Lymphoma. BB-IND 3323 Harwood SJ - Principal Investigator, Webster W, Co-Investigator Coulter Pharmaceutical, Palo Alto, Ca $56,000 to date 

1998 to 2001 A prospective Study of the AcuTect Imaging Characteristics of Patients with Acute Deep Vein Thrombosis and Patients with Post Phlebitic Syndrome. (Phase IV). Principal Investigators Webster, W.B., and Harwood, SJ. Diatide, Inc., Londonberry NH. 

1997 to 1998 A Multicenter Open-label Study Evaluating the Safety of Technetium (Tc-99m) P280 in Patients at Risk for Venous Thrombosis. (Phase III) , Principal Investigators Webster, W.B., and Harwood, SJ, Co-Investigators: Camblin J, Hakki S, Webster T, Carroll R. Diatide, Inc., Londonberry NH. 

1997 to 1999 A Multicenter, Double-Blind, Four-Arm, Parallel-Group, Comparative Study to Evaluate the Safety and Efficacy of Sn-117m DTPA and Metastron for Palliation of Bone Pain from Osseous Metastases in Prostate Cancer Patients. (Phase III) Harwood SJ - Principal Investigator, Webster W, Sochet A, Hakki S, Tantranond P, Hudson P, Morrissey M, Gibbons, L. Diatide, Inc., Londonberry NH. 

1997 to 2001 A Multi-Center Study Evaluating the Safety and Efficacy of Technetium (Tc99m) P829 for the Detection and Localization of Cancer in the Lung.(Phase III) Harwood SJ - Principal Investigator, Webster W, Carroll R, Parikh SL, Bonilla-Santiago J, Tannenbaum M, Riveron E, Morrissey M. Diatide, Inc., Londonberry NH. 

1997 to 2001 Utility of LymphoScan Imaging in the Detection of Residual Tumor after Chemo and/or Radiotherapy in Patients with Non-Hodgkin=s Lymphoma (Protocol IM-D-LL2-05). (Phase III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Immunomedics Corp., Newark, NJ. 

1997 to 2001 The Utility of LymphoScan Imaging in the Localization and Staging of Patients with Non-Hodgkin=s Lymphoma (Protocol IM-D-LL2-05).(Phase III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Immunomedics Corp., Newark, NJ. 

1997 to 1999 Pilot Study Evaluating the Safety and Efficacy of Technetium Tc99m P280 In the Detection of Carotid Artery Thrombi. (Phase II/III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Diatide, Inc., Londonberry NH. 

1996 to 1997 Protocol Number: 280-11, A Multi-Center, Open Label Study evaluating the Pharmacokinetics and Radiation Dosimetry of Technetium Tc99m P280 in Patients at Risk for Venous Thrombosis.(Phase III) Harwood, SJ, and Webster, W.B. Principal Investigators. Diatide, Inc., Londonberry NH. 

1994 to 1997 Protocol Number IM-D-MN3-15, Comparative Pharmacokinetics, Dosimetry and In-Vivo Stability of Two Formulations of 99mTc-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoScanTM) in Patients Undergoing Arthroscopic Procedures. (Phase II/III - Bioequivalence of commercial scale-up) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1994 to 1998 Protocol Number 1033-PK Pharmacokinet­ics of Tc-99m-Labelled Anti-CEA Antibody IMMU-4 Lot (Phase II/III)Commercial scale up) #304121 in Patients with Known Colorectal Carcinoma. Webster, WB, Principal Investigator. Immunomedics Corp., Newark, NJ. 

1992 to 1998 Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) in the Detection of Infected Prosthetic Joints.(Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 to 1998 Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) for the Diagnosis of Long Bone Osteomyelitis. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 to 1998 Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) for the Diagnosis of Osteomyelitis in Patients with Diabetic Foot Ulcers.(Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1993 to 1994 Pharmacokinetics, Dosimetry, and Detection of Lung Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1993 to 1994 Pharmacokinetics, Dosimetry and Imaging of Tc-99m-labelled Anti-CEA Antibody IMMU-4 Lot (Commercial Scale Up) #304121 in Patients with Known Colorectal Carcinoma. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ.. 

1992 to 1993 Detection of Lung Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 Evaluation of Safety and Efficacy in Detection of Non-Hodgkin's B-Cell Lymphoma by Diagnostic Imaging of FAB' Fragment of the Anti-Lymphoma (B-Cell) Antibody IMMU-LL-2 Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 Detection of Breast Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody IMMU-4 Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 Detection of Hepatocellular Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-AFP Antibody IMMU-31 Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 Radioimmunodetection of Residual Recurrent or Metastatic Trophoblastic and Germinal Cell Tumors using 99mTc-Anti-hCG or Anti-AFP Antibody fab' Fragment. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. 

1992 to 1993 Radioimmunoscintigraphy of Recurrent of Metastatic Colorectal Cancer with 99Tc-88BV59H21-2V67-66, A Totally Human Antibody. Phase III Multi-center Study. (Phase III) Carroll RG, Principal Investigator, Webster WB, Co-Investigator. Organon Tekinika/Biotechnology Research Institute, 1330A Piccard Drive, Rockville, MD. 

1992 to 1993 Preoperative Immunoscintigraphy and Intraoperative Oncoprobe Assisted Detection of Colorectal Carcinoma after Intravenous Administration of 99Tc-88BV59H21-2. (Phase III) Carroll RG, Principal Investigator, Webster WB, Co-Investigator. Organon Tekinika/Biotechnology Research Institute, 1330A Piccard Drive, Rockville, MD. 

1991 to 1994 Post-Doctoral Fellowship (2 years) - Biotechnology: Antibody Immunoconjugates and Immunotherapeutics. Webster WB, Principal Preceptor, Glaxo Pharmaceutical, Research Triangle, N.C., $ 81,000 

1990 to 1993 Safety and Preliminary Efficacy of Intravenous Administration of 111In-CYT-356 in the imaging of Prostate Cancer: Pre-surgical Staging, Dosimetry. (Phase III) Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ. 

1990 to 1993 Phase I/II Clinical Study: Detection of Colorectal Carcinoma Using IVP ZCE025, an 111In-Labeled Anti-CEA MoAb (Dose Ranging Protocol). (Phase III) Carroll RG, Principal Investigator, Webster WB, Co-Investigator. Hybritech, La Jolla, Ca. 

1989 to 1993 Repeat Intravenous Infusions of 111In-CYT-103 in the Imaging and Detection of Recurrent Colorectal Carcinoma. (Phase III) Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ. 

1989 to 1990 111In-CYT-103 in the Imaging of Occult Colorectal Carcinoma: Dosimetry. (Phase III) Harwood and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ 1989. 

1988 to 1989 Phase III Study of CYT-103 111In in the Imaging of Colorectal Carcinoma: Pre-surgical Staging. Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ. 

1988 to 1989 Phase III Study of CYT-103 111In in the Imaging of Occult Colorectal Carcinoma. (Phase III) Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ. 

1988 Phase I/II Study of 111In-CYT-103 in the Imaging of Colorectal Carcinoma. Harwood SJ and Webster WB, Co-Principal Investigators. Cytogen Corporation, Princeton, NJ. 

1987 Specificity of ZCE 025 (Fab')2 Localization In Human Colorectal Cancer, VA Merit Review Board, Robert G. Carroll, Principal Investigator and W. B. Webster, Co-Investigator,

GRANTS and APPROVED PROTOCOLS, CLINICAL PRACTICE

 1998 to 2001 The Role of TPFI Levels with Enoxaparin Use in DVT Prophylaxis of Major Surgery (VA Career Development - Type I). Sam I. Hakki, MD, Principal Investigator, Robson, MC and Webster, W.B. Co-investigators. 

1997 to 2001 Incidence of Nocturia and Relationship of Time of Administration in Veteran Population taking Alpha-Adrenergic Blocking Agents for the Treatment of Benign Prostatic Hyperplasia. Shaw B, Principal Investigator Webster, W.B. Co-investigator. Resident Project Bay Pines VAMC. 

1997 to 2001 Evaluation of Metered Dose Inhaler Delivery Above Specified Number of Inhalations. Roman L, Principal Investigator Webster W, Co-investigator. Resident Project Bay Pines VAMC 

1997 to 2001 Evaluation of Increased Serum Glucose Levels in Patients receiving Protease Inhibitors. Holloway FD Principal Investigator, Webster, W.B. Co-investigator. Resident Project Bay Pines VAMC. 

1997 to 2001 Therapeutic Drug Monitoring in Patients Treated for Hyperlipidemia. Jackson N, Webster W, Resident Research Bay Pines VAMC 

1997 to 2001 A survey of Patient=s Perception of an Ambulatory Care Pharmacist in a Home Based Primary Care Setting. Calara R, Principal Investigator Webster WB, Laucka P, Co-investigators. Resident Project, Bay Pines VAMC. 

1997 to 2001 Effects of Enoxaparin on TFPI and Anti-Xa Release in Prophylaxis of VTED in Hip of Knee Arthroplasty Surgery. Hakki S, Camblin J, Webster WB, Hill K, Fareed T. Bay Pines VAMC, Extramural funding pending. 

1995 to 1997 Weight-Based Dosing of Heparin in Coronary Care. Nowacki,Gail, Rozance, Victor, Webster, WB. Unfunded Resident Research. 

1988 Impact of a Pharmacy Based Phlebotomy service Integrated Into Aminoglycoside Clinical Pharmacokinetics Team. Lewis MJ, Principal Investigator, Webster WB, Co-Investigator. Bristol Laboratories.

PROCEDURES and RESEARCH ACTIVITIES

1997 Procedure: Reverse phase gradient HPLC for: Protocol Number: 280-11, A Multi-Center, Open Label Study evaluating the Pharmacokinetics and Radiation Dosimetry of Technetium Tc99m P280 in Patients at Risk for Venous Thrombosis.(Phase III) 

1995 Supporting authority for hearing before FDA/CBER Rockville, Md for protocol below 

1994 Procedure: Size exclusion HPLC with radio detection for protocol below 1994 Authored pharmacokinetic and bioequivalence portions of the protocol accepted by FDA: Protocol Number IM-D-MN3-15, Comparative Pharmacokinetics, Dosimetry and In-Vivo Stability of Two Formulations of 99mTc-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoScanTM) in Patients Undergoing Arthroscopic Procedures. (Phase II/III - Bioequivalence of commercial scale-up) 

1994 Designed a retrospective cohort pharmacokinetic study for bioequivalence of investigational and commercial scale-up products -- Analysis accepted by FDA/CBER and product accepted: Protocol Number 1033-PK Pharmacokinet­ics of Tc-99m-Labelled Anti-CEA Antibody IMMU-4 Lot (Phase II/III)Commercial scale up) #304121 in Patients with Known Colorectal Carcinoma. 1990 Co-Authored pharmacokinetic portion of FDA accepted protocol: Safety and Preliminary Efficacy of Intravenous Administration of 111In-CYT-356 in the imaging of Prostate Cancer: Pre-surgical Staging, Dosimetry. (Phase III) 

1988 Co-Authored pharmacokinetic portion of FDA accepted protocol: Phase I/II Study of 111In-CYT-103 in the Imaging of Colorectal Carcinoma. 

1987 Authored pharmacokinetic and statistical analysis portion of approved VA Merit grant: Specificity of ZCE 025 (Fab')2 Localization In Human Colorectal Cancer 1986 to 2001 Pharmacokinetics and Tissue Distribution of Radiolabeled Monoclonal Antibodies and other Radioimmunodiagnostics and Radioimmunotherapeutics In association with: Steven J.Harwood, M.D., Ph.D., Robert G. Carroll, M.D. 

1982 to 1984 Stereospecific Binding of Propranolol to Serum Proteins In association with: John A. Pieper, Pharm.D. 

1980 to 1982 Determination of Pancreatic Alpha Subtype Receptors by Radioligand Binding Technique In association with: Mona M. McConnaughey, Ph.D.

FUNDING: GRANTS and APPROVED PROTOCOLS as 5/27/1999

1998 to present CP-98-020 Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin’s Lymphoma. BB-IND 3323 Harwood SJ - Principal Investigator, Webster W, Co-Investigator Coulter Pharmaceutical, Palo Alto, Ca $16,000 to date
1998 to present A prospective Study of the AcuTect Imaging Characteristics of Patients with Acute Deep Vein Thrombosis and Patients with Post Phlebitic Syndrome. (Phase IV) Harwood, SJ, and Webster, W.B. Principal Investigators. Diatide, Inc., Londonberry NH. $ 79.000.
1997 to present Effects of Enoxaparin on TFPI and Anti-Xa Release in Prophylaxis of VTED in Hip of Knee Arthroplasty Surgery. Hakki S, Camblin J, Webster WB, Hill K, Fareed T. Bay Pines VAMC, Extramural funding pending.
1997 to present A Multicenter Open-label Study Evaluating the Safety of Technetium (Tc-99m) P280 in Patients at Risk for Venous Thrombosis. (Phase III) Harwood SJ - Principal Investigator, Webster W, Camblin J, Hakki S, Webster T, Carroll R. Diatide, Inc., Londonberry NH.
1997 to present A Multicenter, Double-Blind, Four-Arm, Parallel-Group, Comparative Study to Evaluate the Safety and Efficacy of Sn-117m DTPA and Metastron for Palliation of Bone Pain from Osseous Metastases in Prostate Cancer Patients. (Phase III) Harwood SJ - Principal Investigator, Webster W, Sochet A, Hakki S, Tantranond P, Hudson P, Morrissey M, Gibbons, L. Diatide, Inc., Londonberry NH.
1997 to present A Multi-Center Study Evaluating the Safety and Efficacy of Technetium (Tc99m) P829 for the Detection and Localization of Cancer in the Lung.(Phase III) Harwood SJ - Principal Investigator, Webster W, Carroll R, Parikh SL, Bonilla-Santiago J, Tannenbaum M, Riveron E, Morrissey M. Diatide, Inc., Londonberry NH.
1997 to present Utility of LymphoScan Imaging in the Detection of Residual Tumor after Chemo and/or Radiotherapy in Patients with Non-Hodgkin’s Lymphoma (Protocol IM-D-LL2-05). (Phase III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Immunomedics Corp., Newark, NJ.
1997 to present The Utility of LymphoScan Imaging in the Localization and Staging of Patients with Non-Hodgkin’s Lymphoma (Protocol IM-D-LL2-05).(Phase III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Immunomedics Corp., Newark, NJ.
1997 to present Pilot Study Evaluating the Safety and Efficacy of Technetium Tc99m P280 In the Detection of Carotid Artery Thrombi. (Phase II/III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Diatide, Inc., Londonberry NH.
1997 to present Protocol Number: 829-34, A Multi-Center Study Evaluating the Safety and Efficacy of Technetium Tc99m P829 for the Detection and Localization of Non-Small Cell Lung Cancer. (Phase III) Webster, W.B. and Harwood, SJ Co-Principal Investigators. Diatide, Inc., Londonberry NH.
1996 to 1997 Protocol Number: 280-11, A Multi-Center, Open Label Study evaluating the Pharmacokinetics and Radiation Dosimetry of Technetium Tc99m P280 in Patients at Risk for Venous Thrombosis.(Phase III) Harwood, SJ, and Webster, W.B. Principal Investigators. Diatide, Inc., Londonberry NH. $ 65.000.
1994 to present Protocol Number IM-D-MN3-15, Comparative Pharmacokinetics, Dosimetry and In-Vivo Stability of Two Formulations of 99mTc-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoScanTM) in Patients Undergoing Arthroscopic Procedures. (Phase II/III - Bioequivalence of commercial scale-up) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 60,000 to date.
1994 to present Protocol Number 1033-PK Pharmacokinet­ics of Tc-99m-Labelled Anti-CEA Antibody IMMU-4 Lot (Phase II/III)Commercial scale up) #304121 in Patients with Known Colorectal Carcinoma. Webster, WB, Principal Investigator. Immunomedics Corp., Newark, NJ. $ 10,000 to date.
1992 to present Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) in the Detection of Infected Prosthetic Joints.(Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 25,000 to date.
1992 to present Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) for the Diagnosis of Long Bone Osteomyelitis. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 25,000 to date.
1992 to present Safety and Efficacy of Tc-99m-Labeled Anti-Granulocyte Antibody Fab' Fragment (IMMU-MN3) for the Diagnosis of Osteomyelitis in Patients with Diabetic Foot Ulcers.(Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 25,000 to date.
1993 to 1994 Pharmacokinetics, Dosimetry, and Detection of Lung Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 35,000.
1993 to 1994 Pharmacokinetics, Dosimetry and Imaging of Tc-99m-labelled Anti-CEA Antibody IMMU-4 Lot (Commercial Scale Up) #304121 in Patients with Known Colorectal Carcinoma. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 35,000.
1992 to 1993 Detection of Lung Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ. $ 75,000.
1992 Evaluation of Safety and Efficacy in Detection of Non-Hodgkin's B-Cell Lymphoma by Diagnostic Imaging of FAB' Fragment of the Anti-Lymphoma (B-Cell) Antibody IMMU-LL-2 Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ, $ 25,000.
1992 Detection of Breast Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-CEA Antibody IMMU-4 Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ.
1992 Detection of Hepatocellular Carcinoma by Diagnostic Imaging of FAB' Fragment of the Anti-AFP Antibody IMMU-31 Labeled with Tc-99m. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ.
1992 Radioimmunodetection of Residual Recurrent or Metastatic Trophoblastic and Germinal Cell Tumors using 99mTc-Anti-hCG or Anti-AFP Antibody fab' Fragment. (Phase III) Harwood, SJ and Webster, WB, Principal Investigators. Immunomedics Corp., Newark, NJ.
1992 to 1993 Radioimmunoscintigraphy of Recurrent of Metastatic Colorectal Cancer with 99Tc-88BV59H21-2V67-66, A Totally Human Antibody. Phase III Multi-center Study. (Phase III) Carroll RG, Principal Investigator, Webster WB, Co-Investigator. Organon Tekinika/Biotechnology Research Institute, 1330A Piccard Drive, Rockville, MD. $60,000.00
1992 to 1993 Preoperative Immunoscintigraphy and Intraoperative Oncoprobe Assisted Detection of Colorectal Carcinoma after Intravenous Administration of 99Tc-88BV59H21-2. (Phase III) Carroll RG, Principal Investigator, Webster WB, Co-Investigator. Organon Tekinika/Biotechnology Research Institute, 1330A Piccard Drive, Rockville, MD.
1991 to 1994 Post-Doctoral Fellowship (2 years) - Biotechnology: Antibody Immunoconjugates and Immunotherapeutics. Webster WB, Principal Preceptor, Glaxo Pharmaceutical, Research Triangle, N.C., $ 81,000
1990 to 1993 Safety and Preliminary Efficacy of Intravenous Administration of 111In-CYT-356 in the imaging of Prostate Cancer: Pre-surgical Staging, Dosimetry. (Phase III) Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ, $ 35,000 (to date)
1990 to 1993 Phase I/II Clinical Study: Detection of Colorectal Carcinoma Using IVP ZCE025, an 111In-Labeled Anti-CEA MoAb (Dose Ranging Protocol). (Phase III) Carroll RG, Principal Investigator, Webster WB, Co-Investigator. Hybritech, La Jolla, Ca, $ 30,000 (to date)
1989 to 1993 Repeat Intravenous Infusions of 111In-CYT-103 in the Imaging and Detection of Recurrent Colorectal Carcinoma. (Phase III) Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ, $ 200,000 (to date)
1989 to 1990 111In-CYT-103 in the Imaging of Occult Colorectal Carcinoma: Dosimetry. (Phase III) Harwood and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ 1989, $ 34,300
1988 to 1989 Phase III Study of CYT-103 111In in the Imaging of Colorectal Carcinoma: Pre-surgical Staging. Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ, $ 100,000
1988 to 1989 Phase III Study of CYT-103 111In in the Imaging of Occult Colorectal Carcinoma. (Phase III) Harwood SJ and Webster WB, Principal Investigators. Cytogen Corporation, Princeton, NJ, $ 54,648
1988 Impact of a Pharmacy Based Phlebotomy service Integrated Into Aminoglycoside Clinical Pharmacokinetics Team. Lewis MJ, Principal Investigator, Webster WB, Co-Investigator. Bristol Laboratories, $ 10,000
1988 Phase I/II Study of 111In-CYT-103 in the Imaging of Colorectal Carcinoma. Harwood SJ and Webster WB, Co-Principal Investigators. Cytogen Corporation, Princeton, NJ, $ 60,000
1987 Specificity of ZCE 025 (Fab')2 Localization In Human Colorectal Cancer, VA Merit Review Board, Robert G. Carroll, Principal Investigator and W. B. Webster, Co-Investigator, $ 60,000

CONTACT

Desktop Version